These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8792779)

  • 21. Patterns of health care costs associated with depression and substance abuse in a national sample.
    Druss BG; Rosenheck RA
    Psychiatr Serv; 1999 Feb; 50(2):214-8. PubMed ID: 10030479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consequences of drug abuse and HIV/AIDS in China: recommendations for integrated care of HIV-infected drug users.
    Li X; He G; Wang H; Williams AB
    AIDS Patient Care STDS; 2009 Oct; 23(10):877-84. PubMed ID: 19799494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How cost-of-illness studies can be made more useful for illicit drug policy analysis.
    Moore TJ; Caulkins JP
    Appl Health Econ Health Policy; 2006; 5(2):75-85. PubMed ID: 16872249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners.
    Vassall A; Compernolle P
    Health Policy; 2006 Nov; 79(1):1-15. PubMed ID: 16388874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spending on substance abuse treatment: how much is enough?
    Meara E; Frank RG
    Addiction; 2005 Sep; 100(9):1240-8. PubMed ID: 16128713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Training the next generation of providers in addiction medicine.
    Rasyidi E; Wilkins JN; Danovitch I
    Psychiatr Clin North Am; 2012 Jun; 35(2):461-80. PubMed ID: 22640766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can we better prioritize resources for cost-utility research?
    Neumann PJ; Rosen AB; Greenberg D; Olchanski NV; Pande R; Chapman RH; Stone PW; Ondategui-Parra S; Nadai J; Siegel JE; Weinstein MC
    Med Decis Making; 2005; 25(4):429-36. PubMed ID: 16061895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AIDS: what does economics have to offer?
    Hanson K
    Health Policy Plan; 1992 Dec; 7(4):315-28. PubMed ID: 10123385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Service-level costing of drug abuse treatment.
    Anderson DW; Bowland BJ; Cartwright WS; Bassin G
    J Subst Abuse Treat; 1998; 15(3):201-11. PubMed ID: 9633032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monetary conversion factors for economic evaluations of substance use disorders.
    McCollister K; Yang X; Sayed B; French MT; Leff JA; Schackman BR
    J Subst Abuse Treat; 2017 Oct; 81():25-34. PubMed ID: 28847452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychosocial and behavioral factors associated with risk of sexually transmitted diseases, including human immunodeficiency virus infection, among urban high school students.
    Shafer MA; Boyer CB
    J Pediatr; 1991 Nov; 119(5):826-33. PubMed ID: 1941394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Income and employment of people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders.
    Conover CJ; Arno P; Weaver M; Ang A; Ettner SL
    J Ment Health Policy Econ; 2006 Jun; 9(2):71-86. PubMed ID: 17007485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-effectiveness of addiction care].
    Suijkerbuijk AW; van Gils PF; Greeven PG; de Wit GA
    Tijdschr Psychiatr; 2015; 57(7):498-507. PubMed ID: 26189418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs of care for people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders.
    Conover CJ; Weaver M; Ang A; Arno P; Flynn PM; Ettner SL;
    AIDS Care; 2009 Dec; 21(12):1547-59. PubMed ID: 20024734
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.